BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27209235)

  • 1. Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors.
    An Y; Lee E; Yu Y; Yun J; Lee MY; Kang JS; Kim WY; Jeon R
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3067-3072. PubMed ID: 27209235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
    Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.
    Cai J; Li L; Hong KH; Wu X; Chen J; Wang P; Cao M; Zong X; Ji M
    Bioorg Med Chem; 2014 Nov; 22(21):5813-23. PubMed ID: 25270403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
    Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
    Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
    Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
    Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
    Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and biological evaluation of 2-aminobenzothiazole derivatives as Aurora B kinase inhibitors.
    Lee E; An Y; Kwon J; Kim KI; Jeon R
    Bioorg Med Chem; 2017 Jul; 25(14):3614-3622. PubMed ID: 28529042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of novel phenyldiazepine and pyridodiazepine based Aurora kinase inhibitors.
    Tamizharasan N; Gajendran C; Kristam R; Sulochana SP; Sivanandhan D; Mullangi R; Mathivathanan L; Hallur G; Suresh P
    Bioorg Chem; 2020 Jun; 99():103800. PubMed ID: 32283344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.
    Qi B; Xu X; Yang Y; He H; Yue X
    Bioorg Med Chem; 2019 Sep; 27(17):3825-3835. PubMed ID: 31307762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
    Desai S; Desai V; Shingade S
    Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer.
    Dokla EME; Abdel-Aziz AK; Milik SN; Mahmoud AH; Saadeldin MK; McPhillie MJ; Minucci S; Abouzid KAM
    Bioorg Chem; 2021 Dec; 117():105451. PubMed ID: 34736137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold.
    Long L; Luo Y; Hou ZJ; Ma HJ; Long ZJ; Tu ZC; Huang LJ; Liu Q; Lu G
    Eur J Med Chem; 2018 Feb; 145():805-812. PubMed ID: 29358147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells.
    Omar AME; AboulWafa OM; Amr ME; El-Shoukrofy MS
    Bioorg Chem; 2021 Apr; 109():104752. PubMed ID: 33657444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
    Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
    Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
    Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
    Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of the anticancer activity of 2-amino-aryl-7-aryl-benzoxazole compounds.
    Khajondetchairit P; Phuangsawai O; Suphakun P; Rattanabunyong S; Choowongkomon K; Gleeson MP
    Chem Biol Drug Des; 2017 Nov; 90(5):987-994. PubMed ID: 28544428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.
    Song D; Park Y; Yoon J; Aman W; Hah JM; Ryu JS
    Bioorg Med Chem; 2014 Sep; 22(17):4855-66. PubMed ID: 25042560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.